|
Name |
5-Chloro-6,8,10-trihydroxy-l-methoxy-3-methyl-9(10H)-anthracenon
|
Molecular Formula | C16H13ClO5 | |
IUPAC Name* |
4-chloro-1,3,10-trihydroxy-8-methoxy-6-methyl-10H-anthracen-9-one
|
|
SMILES |
CC1=CC2=C(C(=C1)OC)C(=O)C3=C(C2O)C(=C(C=C3O)O)Cl
|
|
InChI |
InChI=1S/C16H13ClO5/c1-6-3-7-11(10(4-6)22-2)16(21)12-8(18)5-9(19)14(17)13(12)15(7)20/h3-5,15,18-20H,1-2H3
|
|
InChIKey |
XLQCTJILGLSGOE-UHFFFAOYSA-N
|
|
Synonyms |
CHEMBL485458; 5-Chloro-6,8,10-trihydroxy-l-methoxy-3-methyl-9(10H)-anthracenon; 5-chloro-6,8,10-trihydroxy-1-methoxy-3-methyl-9(10H)-anthracenone
|
|
CAS | NA | |
PubChem CID | 10448715 | |
ChEMBL ID | CHEMBL485458 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 320.72 | ALogp: | 3.0 |
HBD: | 3 | HBA: | 5 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 87.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 22 | QED Weighted: | 0.748 |
Caco-2 Permeability: | -5.075 | MDCK Permeability: | 0.00000768 |
Pgp-inhibitor: | 0.007 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.139 | 20% Bioavailability (F20%): | 0.025 |
30% Bioavailability (F30%): | 0.959 |
Blood-Brain-Barrier Penetration (BBB): | 0.004 | Plasma Protein Binding (PPB): | 97.49% |
Volume Distribution (VD): | 0.503 | Fu: | 5.48% |
CYP1A2-inhibitor: | 0.925 | CYP1A2-substrate: | 0.898 |
CYP2C19-inhibitor: | 0.141 | CYP2C19-substrate: | 0.067 |
CYP2C9-inhibitor: | 0.691 | CYP2C9-substrate: | 0.821 |
CYP2D6-inhibitor: | 0.18 | CYP2D6-substrate: | 0.354 |
CYP3A4-inhibitor: | 0.071 | CYP3A4-substrate: | 0.104 |
Clearance (CL): | 8.851 | Half-life (T1/2): | 0.737 |
hERG Blockers: | 0.012 | Human Hepatotoxicity (H-HT): | 0.051 |
Drug-inuced Liver Injury (DILI): | 0.931 | AMES Toxicity: | 0.566 |
Rat Oral Acute Toxicity: | 0.147 | Maximum Recommended Daily Dose: | 0.91 |
Skin Sensitization: | 0.932 | Carcinogencity: | 0.112 |
Eye Corrosion: | 0.057 | Eye Irritation: | 0.946 |
Respiratory Toxicity: | 0.59 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005319 | 1.000 | D07MGA | 0.364 | ||||
ENC002766 | 0.639 | D06GCK | 0.306 | ||||
ENC002767 | 0.532 | D0AZ8C | 0.287 | ||||
ENC002031 | 0.526 | D0K8KX | 0.266 | ||||
ENC002107 | 0.513 | D01XWG | 0.266 | ||||
ENC000939 | 0.506 | D0C1SF | 0.265 | ||||
ENC000362 | 0.468 | D07VLY | 0.260 | ||||
ENC005490 | 0.458 | D0C9XJ | 0.260 | ||||
ENC002039 | 0.454 | D04AIT | 0.258 | ||||
ENC004200 | 0.449 | D0R9WP | 0.243 |